Markets

Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026

Jul 23, 2026 · 07:02 AM ET· updated 2h ago

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial

Why It Matters

Beam Therapeutics will show new results from testing a medicine designed to fix a genetic problem that hurts the lungs. When a company shares positive trial updates, it can show their medicine is working, which makes investors more interested.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BEAM25.74

-0.90 (-3.38%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.